Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen (BIIB) Q4 Earnings & Sales Miss Estimates, Stock Falls
12:21pm, Tuesday, 13'th Feb 2024
Biogen (BIIB) misses fourth-quarter estimates for earnings and sales. Sales of Tecfidera, Tysabri & Spinraza decline.
Here's What Key Metrics Tell Us About Biogen Inc. (BIIB) Q4 Earnings
10:36am, Tuesday, 13'th Feb 2024
The headline numbers for Biogen Inc. (BIIB) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street e
Biogen Inc. (BIIB) Lags Q4 Earnings and Revenue Estimates
09:21am, Tuesday, 13'th Feb 2024
Biogen Inc. (BIIB) came out with quarterly earnings of $2.95 per share, missing the Zacks Consensus Estimate of $3.16 per share. This compares to earnings of $4.05 per share a year ago.
Biogen's quarterly results miss expectations amid slow launch of Alzheimer's treatment
07:21am, Tuesday, 13'th Feb 2024
Biogen Inc. BIIB, +1.56% on Tuesday reported fourth-quarter results that fell short of Wall Street expectations as uptake of its newer drugs failed to offset declining multiple-sclerosis product sales
Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
07:03am, Tuesday, 13'th Feb 2024
The results come amid the rollout of Biogen and Eisai's Leqembi, the first drug found to slow the progression of Alzheimer's to win FDA approval.
Biogen's rare genetic disorder drug gets approval in EU
04:21pm, Monday, 12'th Feb 2024
Biogen said on Monday the European Commission has approved its drug for treating a rare genetic disorder that causes progressive damage to the nervous system, in adults and adolescents aged 16 years a
Wall Street Brunch: Retail Inflation In Focus
11:23am, Sunday, 11'th Feb 2024
This week, traders will have a lot of economic data to digest, including retail sales, manufacturing measures, jobless claims, and the consumer price index. The market is now pricing in a 16% chance o
Biogen Inc. (BIIB) Stock Sinks As Market Gains: Here's Why
06:51pm, Thursday, 08'th Feb 2024
In the most recent trading session, Biogen Inc. (BIIB) closed at $240.30, indicating a -0.1% shift from the previous trading day.
7 Biotech Stocks Fighting America's Deadliest Diseases
04:10pm, Thursday, 08'th Feb 2024
Unlike many other market segments, biotech stocks stand out for their direct relevance. For example, investors who typically wager on aerospace and defense plays usually aren't fighter pilots.
Can Biogen (BIIB) Keep the Beat Streak Alive in Q4 Earnings?
11:35am, Thursday, 08'th Feb 2024
Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have risen.
Stay Ahead of the Game With Biogen Inc. (BIIB) Q4 Earnings: Wall Street's Insights on Key Metrics
10:21am, Thursday, 08'th Feb 2024
Evaluate the expected performance of Biogen Inc. (BIIB) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key met
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Tuesday, 06'th Feb 2024
Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen Inc. (BIIB) Stock Drops Despite Market Gains: Important Facts to Note
06:51pm, Friday, 02'nd Feb 2024
In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $243.72, denoting a -1.66% change from the preceding trading day.
Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm
11:31am, Thursday, 01'st Feb 2024
Biogen (BIIB) aims to build a leading Alzheimer's disease franchise with the new drug Leqembi. The company quits commercializing the controversial Alzheimer's disease drug, Aduhelm.
Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments
11:43am, Wednesday, 31'st Jan 2024
Biogen said its decision to drop Aduhelm, which had a polarizing approval and launch, was "not related to any safety or efficacy concerns."
